1. Home
  2. XAIR vs PRHI Comparison

XAIR vs PRHI Comparison

Compare XAIR & PRHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XAIR
  • PRHI
  • Stock Information
  • Founded
  • XAIR 2011
  • PRHI 2009
  • Country
  • XAIR United States
  • PRHI United States
  • Employees
  • XAIR N/A
  • PRHI N/A
  • Industry
  • XAIR Medical/Dental Instruments
  • PRHI Property-Casualty Insurers
  • Sector
  • XAIR Health Care
  • PRHI Finance
  • Exchange
  • XAIR Nasdaq
  • PRHI Nasdaq
  • Market Cap
  • XAIR 17.0M
  • PRHI 13.7M
  • IPO Year
  • XAIR N/A
  • PRHI N/A
  • Fundamental
  • Price
  • XAIR $2.50
  • PRHI $1.29
  • Analyst Decision
  • XAIR Strong Buy
  • PRHI
  • Analyst Count
  • XAIR 1
  • PRHI 0
  • Target Price
  • XAIR $11.00
  • PRHI N/A
  • AVG Volume (30 Days)
  • XAIR 466.2K
  • PRHI 2.6M
  • Earning Date
  • XAIR 11-10-2025
  • PRHI 11-13-2025
  • Dividend Yield
  • XAIR N/A
  • PRHI N/A
  • EPS Growth
  • XAIR N/A
  • PRHI N/A
  • EPS
  • XAIR N/A
  • PRHI 2.45
  • Revenue
  • XAIR $4,782,000.00
  • PRHI $52,654,000.00
  • Revenue This Year
  • XAIR $263.75
  • PRHI N/A
  • Revenue Next Year
  • XAIR $148.43
  • PRHI N/A
  • P/E Ratio
  • XAIR N/A
  • PRHI $0.46
  • Revenue Growth
  • XAIR 168.20
  • PRHI N/A
  • 52 Week Low
  • XAIR $2.02
  • PRHI $0.42
  • 52 Week High
  • XAIR $13.52
  • PRHI $2.21
  • Technical
  • Relative Strength Index (RSI)
  • XAIR 52.02
  • PRHI N/A
  • Support Level
  • XAIR $2.16
  • PRHI N/A
  • Resistance Level
  • XAIR $2.53
  • PRHI N/A
  • Average True Range (ATR)
  • XAIR 0.13
  • PRHI 0.00
  • MACD
  • XAIR 0.03
  • PRHI 0.00
  • Stochastic Oscillator
  • XAIR 91.89
  • PRHI 0.00

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Share on Social Networks: